Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3060 143 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Incyte markets the first JAK inhibitor approved for any use, Jakafi (ruxolitinib). Add an interesting pipeline, and INCY is fun to follow, if not own. Please contribute, and good luck!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3060>> “With this agreement, Gilead now has compounds targeting four unique siscaram(o)uche-last Friday
3059>> some tox issues << from Doug H...... (regarding pascaram(o)uche1December 10 Tue, Dec 9, 2014, 11:54AM EST Infinity Reports New Results fscaram(o)uche-December 9
3057INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company ( LLY) and Incynigel bates-December 9 from Doug Heuring, comments from RBC..... GILD comments relevanscaram(o)uche-December 8
3055Good call. Only sold 1/4 of a large position (still largest by a long way), so tuck-December 4
3054>> that sounds a tad low << Yeah, never got there. And today, therscaram(o)uche-December 4
3053We could use a new moderator to update the board header and we also need a logo SI Ron (Hall Monitor)-November 6
3052More of the same from SITC2014.... immunotherapyofcancer.orgscaram(o)uche-November 6
3051>> 986 is gone from the pipeline chart << j l ?@lomu_j21m21 minutesscaram(o)uche-October 30
3050updated..... GILD - Idelalisib, GS-9901 (GS-9901 not confirmed PI3Kdelta, but lscaram(o)uche-October 29
3049Fun (and probably useless) factoid..... Dr. Khleif is also P.I. at the only siscaram(o)uche-October 24
3048Interesting. Don't think I ever put this abstract up, as it didn't honescaram(o)uche-October 23
3047Wo! NewLink Genetics Announces Exclusive Worldwide Licensingscaram(o)uche-October 20
3046Updated...... Tuck has found another clinical-stage project from Rhizen. GILD scaram(o)uche-October 19
3045Was NOT expecting this..... clinicaltrials.govscaram(o)uche-October 17
3044Talked about panabinostat, and results showing recovery of marrow. Now therescaram(o)uche-October 17
3043986 is gone from the pipeline chart? Stepping in is 793 (no detail beyond "scaram(o)uche-October 16
3042>> Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablscaram(o)uche-October 14
3041PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollectiscaram(o)uche-October 8
3040Housekeeping note...... Xeljanz did $68m in 2nd quarter. Psoriasis trial coscaram(o)uche-October 8
3039Yes. It promptly went to $70.scaram(o)uche-October 7
3038cool..... Bristol-Myers Squibb Announces Collaboration to Evaluascaram(o)uche-October 6
3037Looked like a dedicated seller ("capping") yesterday, on relatively hiscaram(o)uche-October 3
3036<i>Incyte will record this amount as contract revenue in the third quarterscaram(o)uche-October 2
3035Interesting trial...... nilotinib plus rux, Novartis trial,scaram(o)uche-October 2
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.